{
    "organizations": [],
    "uuid": "a1d4534905ee8c0c711d909be417f6cac2ffeff4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-amgen-reports-aimovig-met-all-prim/brief-amgen-reports-aimovig-met-all-primary-secondary-endpoints-idUSFWN1PH13K",
    "ord_in_thread": 0,
    "title": "BRIEF-Amgen Reports Aimovig Met All Primary, Secondary Endpoints",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 22 (Reuters) - Amgen Inc:\n* AMGEN REPORTS AIMOVIGâ„¢ (ERENUMAB) MET ALL PRIMARY AND SECONDARY ENDPOINTS IN UNIQUE PHASE 3B STUDY IN EPISODIC MIGRAINE PATIENTS WHO HAVE FAILED MULTIPLE PRIOR PREVENTIVE TREATMENTS\n* AMGEN INC - FDA HAS SET A PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE OF MAY 17, 2018\n* AMGEN INC - IF APPROVED, NOVARTIS AND AMGEN WILL CO-COMMERCIALIZE AIMOVIG IN U.S.\n* AMGEN INC - SAFETY DATA ARE CONSISTENT WITH PREVIOUS STUDIES OF AIMOVIG TO DATE\n* AMGEN INC - LIBERTY ALSO MET ALL SECONDARY ENDPOINTS, INCLUDING REDUCTION OF MONTHLY MIGRAINE DAYS, REDUCTION IN DAYS NEEDING ACUTE MEDICATION Source text for Eikon: Further company coverage:\n ",
    "published": "2018-01-23T06:02:00.000+02:00",
    "crawled": "2018-01-23T07:40:41.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "amgen",
        "inc",
        "amgen",
        "report",
        "erenumab",
        "met",
        "primary",
        "secondary",
        "endpoint",
        "unique",
        "phase",
        "3b",
        "study",
        "episodic",
        "migraine",
        "patient",
        "failed",
        "multiple",
        "prior",
        "preventive",
        "treatment",
        "amgen",
        "inc",
        "fda",
        "set",
        "prescription",
        "drug",
        "user",
        "fee",
        "act",
        "pdufa",
        "target",
        "action",
        "date",
        "may",
        "amgen",
        "inc",
        "approved",
        "novartis",
        "amgen",
        "aimovig",
        "amgen",
        "inc",
        "safety",
        "data",
        "consistent",
        "previous",
        "study",
        "aimovig",
        "date",
        "amgen",
        "inc",
        "liberty",
        "also",
        "met",
        "secondary",
        "endpoint",
        "including",
        "reduction",
        "monthly",
        "migraine",
        "day",
        "reduction",
        "day",
        "needing",
        "acute",
        "medication",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}